Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Currently meet the DMS-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) criteria for Major Depressive Disorder (MDD)~* The participant must have an ongoing major depressive episode of at least 8 weeks and no more than 18 months~* The participant must have at least 3 lifetime episodes of MDD (including the current episode)~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control~* Participants who are considered a suicide risk~* History of non-response to 2 or more antidepressants (after adequate treatment)~* Participants who have a history of meeting DMS-5 criteria for manic, hypomanic, or mixed episode, obsessive-compulsive disorder, schizophrenia or other psychotic disorder~* Panic disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Open-Label FETZIMA® (Type: EXPERIMENTAL): FETZIMA® (levomilnacipran extended release \[ER\]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
- Double-Blind Placebo (Type: PLACEBO_COMPARATOR): Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
- Double-Blind FETZIMA® (Type: EXPERIMENTAL): FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).